| 臺大學術典藏 |
2020-08-13T06:34:06Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.; Yang C.-H.; Yu C.-J.; JIN-YUAN SHIH; Hsu C.; Yang P.-C.; Su W.-P.;Yang C.-H.;Yu C.-J.;Jin-Yuan Shih;Hsu C.;Yang P.-C. |
| 臺大學術典藏 |
2020-08-13T06:34:05Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; Yang P.-C.; Yu C.-J.; Yang T.-Y.; Yang C.-H.; JIN-YUAN SHIH; Chen K.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:59Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Yang C.-H.; Yang P.-C.; Huang T.-C.; Lin C.-C.; Yu C.-J.; Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-08-12T06:35:54Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
CHONG-JEN YU; Hsu C.; Cheng A.-L.; Yang P.-C.; Kuo S.-H.; Yang C.-H.; Kuo S.-H.;Yang C.-H.;Chong-Jen Yu;Hsu C.;Cheng A.-L.;Yang P.-C. |
| 臺大學術典藏 |
2020-08-12T06:35:50Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.;Yang C.-H.;Chong-Jen Yu;Shih J.-Y.;Hsu C.;Yang P.-C.; Su W.-P.; Yang C.-H.; CHONG-JEN YU; Shih J.-Y.; Hsu C.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-12T06:35:41Z |
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers
|
Chen J.-P.;Lo Y.;Chong-Jen Yu;Hsu C.;Shih J.-Y.;Yang C.-H.; Chen J.-P.; Lo Y.; CHONG-JEN YU; Hsu C.; Shih J.-Y.; Yang C.-H. |
| 臺大學術典藏 |
2020-08-12T06:35:40Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.;Hsu C.;Chang Y.-C.;Chong-Jen Yu;Hsu C.-H.;Lin C.-C.;Cheng A.-L.;Yang P.-C.;Yang C.-H.; Lin Z.-Z.; Hsu C.; Chang Y.-C.; CHONG-JEN YU; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2020-08-12T02:42:39Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Bang-Bin Chen;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Hsu C.;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; BANG-BIN CHEN; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-08-12T02:42:37Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Chao Y.; Hsu C.; Lee R.-C.; Lin Z.-Z.; BANG-BIN CHEN; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lin Z.-Z.;Bang-Bin Chen;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Hsu C.-H.;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C. |
| 臺大學術典藏 |
2020-08-11T08:36:58Z |
Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: A preliminary result
|
PO-CHIN LIANG; Ch'ang H.-J.; Hsu C.; Tseng S.S.; Shih T.T.F.; Wu Liu T. |
| 臺大學術典藏 |
2020-08-11T08:36:56Z |
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer
|
Chang Y.-T.; Chang M.-C.; Wei S.-C.; Tien Y.-W.; Hsu C.; PO-CHIN LIANG; Tsao P.-N.; Jan I.-S.; Wong J.-M. |
| 臺大學術典藏 |
2020-08-11T08:36:51Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; PO-CHIN LIANG; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-08-11T08:36:48Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; Chen C.-H.; Shih T.T.-F.; PO-CHIN LIANG; Liu K.-L. |
| 臺大學術典藏 |
2020-08-11T08:36:46Z |
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide
|
PO-CHIN LIANG; Ch’ang H.-J.; Hsu C.; Chen L.-T.; Shih T.T.F.; Liu T.W. |
| 臺大學術典藏 |
2020-08-11T08:36:45Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; PO-CHIN LIANG; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-08-11T08:36:42Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Po-Chin Liang;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Huo T.-I.; Liao L.-Y.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Lu S.-N. |
| 臺大學術典藏 |
2020-08-07T02:32:19Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; CHIH-HORNG WU; Hsu C.; Chen C.-H.; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2020-08-06T07:51:50Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Liang P.-C.; Liu K.-L.; TIFFANY TING-FANG SHIH; Chen C.-H.; Hsu C.; Wu C.-H.; Chen B.-B.; Shih I.-L. |
| 臺大學術典藏 |
2020-08-06T07:51:48Z |
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide
|
TIFFANY TING-FANG SHIH; Liu T.W.; Chen L.-T.; Hsu C.; Liang P.-C.; Ch’ang H.-J. |
| 臺大學術典藏 |
2020-08-06T07:51:46Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; TIFFANY TING-FANG SHIH |
| 臺大學術典藏 |
2020-08-06T07:51:44Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; TIFFANY TING-FANG SHIH; Hsu C.-Y.; Chen B.-B. |
| 臺大學術典藏 |
2020-07-10T08:16:43Z |
Using standardised measures of health-related quality of life: Critical issues for users and developers
|
Kind, P.;Hsu, C.;Wang, J.-D.;Yao, G.;Tang, J.-L.; Kind, P.; Hsu, C.; Wang, J.-D.; Yao, G.; Tang, J.-L.; KAI-PING GRACE YAO |
| 臺大學術典藏 |
2020-07-09T02:57:04Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Hsu C.-Y. ;Shen Y.-C. ;Chih-Wei Yu ;Hsu C. ;Hu F.-C. ;Hsu C.-H. ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F.; Hsu C.-Y.; Shen Y.-C.; CHIH-WEI YU; Hsu C.; Hu F.-C. |
| 臺大學術典藏 |
2020-07-09T02:57:03Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
CHIH-WEI YU; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; Cheng A.-L.; Hsieh R.-K.; Huo T.-I.; Yang T.-S.; Hsu C. |
| 臺大學術典藏 |
2020-07-09T02:57:02Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; CHIH-WEI YU; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
